Browsing by Author "Mulatero, Paolo"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Comparison of confirmatory tests for the diagnosis of primary aldosteronism
    (ENDOCRINE SOC, 2006) Mulatero, Paolo; Milan, Alberto; Fallo, Francesco; Regolisti, Giuseppe; Pizzolo, Francesca; Fardella, Carlos; Mosso, Lorena; Marafetti, Lisa; Veglio, Franco; Maccario, Mauro
    Context: Primary aldosteronism (PA) is the most frequent form of secondary hypertension, accounting for up to 5-10% of all hypertensive patients, and the diagnosis of PA can present an important challenge for the clinician. After a positive screening test, the diagnosis is confirmed by a suppression test, often an iv saline load test (SLT) or a fludrocortisone suppression test (FST). The FST is considered by many to be the most reliable but is more complex and expensive.
  • Thumbnail Image
    Item
    Familial hyperaldosteronism: an European Reference Network on Rare Endocrine Conditions clinical practice guideline
    (2024) Mulatero, Paolo; Scholl, Ute, I; Fardella, Carlos E.; Charmandari, Evangelia; Januszewicz, Andrzej; Reincke, Martin; Gomez-Sanchez, Celso E.; Stowasser, Michael; Dekkers, Olaf M.
    We describe herein the European Reference Network on Rare Endocrine Conditions clinical practice guideline on diagnosis and management of familial forms of hyperaldosteronism. The guideline panel consisted of 10 experts in primary aldosteronism, endocrine hypertension, paediatric endocrinology, and cardiology as well as a methodologist. A systematic literature search was conducted, and because of the rarity of the condition, most recommendations were based on expert opinion and small patient series. The guideline includes a brief description of the genetics and molecular pathophysiology associated with each condition, the patients to be screened, and how to screen. Diagnostic and treatment approaches for patients with genetically determined diagnosis are presented. The recommendations apply to patients with genetically proven familial hyperaldosteronism and not to families with more than one case of primary aldosteronism without demonstration of a responsible pathogenic variant.